世界の製薬産業における事業提携、ライセンス、投資、M&A動向(2014年第4四半期版)...市場調査レポートについてご紹介

【英文タイトル】Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2014

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q4 2014 15
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q4 2014 15
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q4 2014 17
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q4 2014 18
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2014 19
2.4.1 Actavis to Acquire Allergan for USD66 Billion 19
2.4.2 Medtronic Raises USD17 Billion in Private Placement of Notes 20
2.4.3 Merck Acquires Cubist Pharma for USD9.5 Billion 20
2.4.4 Bayer Raises USD7 Billion in Public Offering Bonds 21
2.4.5 LabCorp to Acquire Covance for USD6.1 Billion 21
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 23
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q4 2014 23
3.1.1 Top M&A Deals in Q4 2014 24
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q4 2013 – Q4 2014 25
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q4 2014 26
3.2.1 Top Initial Public Offerings in Q4 2014 27
3.2.2 Top Secondary Offerings in Q4 2014 28
3.2.3 Top PIPE Deals in Q4 2014 28
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q4 2013-Q4 2014 29
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q4 2013 – Q4 2014 29
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q4 2014 31
3.3.1 Top Venture Financing Deals in Q4 2014 32
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2014 33
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2014 34
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q4 2013 – Q4 2014 35
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q4 2013 – Q4 2014 36
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2013 – Q4 2014 37
3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q4 2014 38
3.4.1 Top Private Equity Deals in Q4 2014 39
3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q4 2013 – Q4 2014 40
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2014 42
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2014 42
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q4 2013 – Q4 2014 44
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 46
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q4 2014 47
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2014 48
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q4 2014 48
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2013 – Q4 2014 49
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q4 2013 – Q4 2014 51
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q4 2013 – Q4 2014 52
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2013 – Q4 2014 53
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q4 2014 55
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q4 2014 55
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2013 – Q4 2014 57
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q4 2014 58
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q4 2014 59
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q4 2014 60
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q4 2013 – Q4 2014 61
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q4 2013 – Q4 2014 63
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2013 – Q4 2014 65
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2013 – Q4 2014 66
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q4 2013 – Q4 2014 68
6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 70
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q4 2013 – Q4 2014 70
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q4 2013 – Q4 2014 72
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2013 – Q4 2014 73
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q4 2013 – Q4 2014 75
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q4 2013 – Q4 2014 77
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q4 2013 – Q4 2014 78
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2013 – Q4 2014 79
7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 80
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q4 2014 80
7.1.1 Oncology – Deals of the Quarter 82
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q4 2014 84
7.2.1 Central Nervous System – Deals of the Quarter 86
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q4 2014 88
7.3.1 Infectious Disease – Deals of the Quarter 89
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q4 2014 92
7.4.1 Immunology – Deals of the Quarter 94
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q4 2014 96
7.5.1 Metabolic Disorders – Deals of the Quarter 97
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q4 2014 100
7.6.1 Cardiovascular – Deals of the Quarter 101
7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q4 2014 103
7.7.1 Gastrointestinal – Deals of the Quarter 104
7.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q4 2014 106
7.8.1 Dermatology – Deals of the Quarter 107
7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q4 2014 109
7.9.1 Respiratory – Deals of the Quarter 110
7.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q4 2014 113
7.10.1 Ophthalmology – Deals of the Quarter 114
8 Deal Summary by Geography 117
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q4 2014 117
8.1.1 North America – Deals of the Quarter 119
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q4 2014 121
8.2.1 Europe – Deals of the Quarter 122
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q4 2014 126
8.3.1 Asia-Pacific – Deals of the Quarter 127
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q4 2014 129
8.4.1 Rest of the World – Deals of the Quarter 130
9 Pharmaceuticals & Healthcare, Global, Top Advisors 132
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q4 2013 – Q4 2014 132
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q4 2013 – Q4 2014 134
10 Appendix 136
11 Further Information 139
11.1 Methodology 139
11.2 About GlobalData 140
11.3 Disclosure information 141
11.4 Disclaimer 141


【レポート販売概要】

■ タイトル:世界の製薬産業における事業提携、ライセンス、投資、M&A動向(2014年第4四半期版)
■ 英文:Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2014
■ 発行日:2015年2月15日
■ 調査会社:GlobalData
■ 商品コード:GDPH0473QD
■ 調査対象地域:グローバル
  • Fluconazole (Dermatophytic Onychomycosis):市場予測と分析(~2022)
    Fluconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Fluconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022”. Dermatophytic onychomycosis (DO) is characterized as being a fungal infection of the nail. Infection can involve the nail unit (nail matrix, nail bed, or nail …
  • ラボラトリーオートメーション装置/ソフトウェアの世界市場:ロボットアーム、マイクロプレートリーダー、LIMS(ラボ情報管理システム)
    The report segments the lab automation market on the basis of equipment and software, application, type of automation, end user, and region. On the basis of applications, the lab automation market is broadly classified into clinical diagnostics, drug discovery, genomics solutions, and proteomics solutions. Drug discovery is a major application of the lab automation market. Developing markets such …
  • グローバル海上保安・国境保安市場(2014-2024):SWOT分析
    Synopsis This report provides readers with an exhaustive analysis of industry characteristics, determining the strengths, weaknesses, opportunities and threats faced by the Maritime and Border Security market. Summary This SWOT analysis of Maritime and Border Security market is a crucial resource for industry executives and anyone looking to gain a better understanding of the market. SDI's "The Gl …
  • 世界の多発性硬化症(MS)市場動向(2012-2016)
    TechNavio's analysts forecast the Global Multiple Sclerosis (MS) Therapeutics market to grow at a CAGR of 3.16 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rising diagnosis and treatment rates. The Global MS Therapeutics market has also been witnessing the emergence of biomarkers. However, the lack of therapies available to manage the progress …
  • Mesa Royalty Trust:石油・ガスの開発・生産動向及びコスト分析- Q1, 2013
    Mesa Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis - Q1, 2013 Summary Mesa Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for k …
  • メニエール病(Meniere Disease):治療薬開発パイプライン動向(2015年上半期版)
    Meniere Disease - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Meniere Disease - Pipeline Review, H1 2015’, provides an overview of the Meniere Disease’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Meniere Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of acti …
  • 半導体パッケージング及び組立装置の世界市場2016-2020
    About Semiconductor Packaging and Assembly Equipment For an integrated chip (IC) to function, it needs to be connected to the package or connected directly to the printed circuit. This involves dicing, wire bonding, and die bonding. This entire process is known as semiconductor packaging and assembly, which is the back-end process of chip formation. The increasing application of semiconductor ICs …
  • Arcan Resources Ltd.:石油・ガスの開発・生産動向及びコスト分析- Q2, 2013
    Arcan Resources Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Arcan Resources Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source f …
  • 補聴器3Dプリント装置の世界市場2019-2023
    About this market The technological advances in 3D printing hearing aid manufacturing are one of the key factors expected to propel the market growth during the forecast period. Several vendors in the market are exploring new 3D printing technologies such as cDLM and DLP to manufacture their products including hearing aids. Furthermore, they are also exploring other processes such as multi-jetting …
  • POC感染症診断の世界市場2015-2019
    About POC infectious diseases POC diagnosis for infectious diseases refers to diagnostic tests performed near the site of patient care. The testing site is usually a patient's bedside, physician's clinic, ICU, operating room, emergency room, or wherever medical care may be necessary. A healthcare professional or a nurse attending the patient will obtain the specimen, perform analysis, and record t …
  • 世界主要国の髄膜炎検査(医療機器)市場
    The report presents a detailed analysis of the Meningitis diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Meningitis definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments:      - Hospitals     - C …
  • Distribution Automation Technology – A Value-Added Dimension for a Smarter Grid
    Distribution Automation Technology - A Value-Added Dimension for a Smarter Grid Summary Distribution Automation (DA) involves any automation deployed in the planning, engineering, construction, operation, and maintenance of a distribution system. It also comprises interactions with the transmission system, interconnected Distributed Energy Resources (DER), and automated interfaces with end-users ( …
  • 世界のユーティリティー産業におけるGIS市場動向(2012-2016)
    TechNavio's analysts forecast the Global GIS market in the Utility industry to grow at a CAGR of 10.37 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing need for knowledge infrastructure. The Global GIS market in the Utility industry has also been witnessing increasing focus on application-specific GIS solutions. However, the lack of awa …
  • 血液凝固/止血分析装置の世界市場予測(~2021): 臨床検査室、PoCT分析装置
    The coagulation analyzer market is projected to reach USD 4.84 Billion by 2021 from USD 2.98 Billion in 2016, at a CAGR of 10.2% from 2016 to 2021. The market consists of various products that are used by clinical laboratories, hospitals, patient self-testing and others. The high incidence and large economic burden of blood related diseases and CVD’s, rise in healthcare spending has resulted in th …
  • 合成繊維の世界市場:ポリエステル類、ポリアミド類、ポリアクリル酸類
    About Synthetic fibers Synthetic fibers are man-made materials that are formed using chemicals that have superior properties as compared to natural fibers. These fibers are created through polymerization of various chemical substances. Synthetic fibers are more durable, easy to dye, stain-resistant and lighter. These fibers are used widely in the Fashion industry for various applications because o …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。